title: Update on evidence for treatment with ranolazine in stable angina.
abstract: Chronic angina represents a major burden for public health systems because of its poor prognosis and its high treatment costs. Ranolazine is an emerging drug recently approved for the treatment of this disease. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. Moreover, this particular mechanism of action also confers on ranolazine a potential antiarrhythmic effect. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
authors.affiliation: Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Switzerland; fedric8@gmail.com.
authors.forename: Federico
authors.initials: F
authors.lastname: Carbone
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Montecucco
authors.forename: François
authors.initials: F
authors.lastname: Mach
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D060050:Angina, Stable / Q000188:drug therapy*; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D000069458:Ranolazine; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000083:Acetanilides; D010879:Piperazines; D026941:Sodium Channel Blockers; D000069458:Ranolazine